| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cartesian Therapeutics, Inc. (RNAC) has 13 insiders with recent SEC Form 4 filings, including 20 buys and 0 sells. RNAC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.65M | $72.80M | - | |
| 10% | 511.6K | $4.31M | - | |
| CEO | 323.5K | $2.72M | - | |
| CFO | 121.2K | $1.02M | - | |
| Other | 94.2K | $793.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2019 | Springer Timothy A49 | Director, 10% Owner | Buy | 10,000 | $1.74 | $17,415.00 | +13.1% | |
| Aug 13, 2019 | Barabe Timothy C49 | Director | Buy | 10,000 | $1.72 | $17,200.00 | +133.5% | |
| Jan 25, 2019 | Farokhzad Omid71 | Director | Buy | 83,333 | $1.50 | $124,999.50 | New | |
| Jan 25, 2019 | Nashat Amir | Director | Buy | 1,166,666 | $1.50 | $1,749,999.00 | +72.6% | |
| Jan 25, 2019 | Springer Timothy A49 | Director | Buy | 4,071,418 | $1.51 | $6,142,904.81 | +863.8% | |
| Nov 17, 2017 | Sands Earl | Chief Medical Officer | Buy | 7,500 | $10.26 | $76,966.50 | New | |
| Nov 14, 2017 | Abraham David | GC, CCO &Corporate Secretary | Buy | 5,405 | $9.25 | $49,996.25 | New | |
| Nov 14, 2017 | Springer Timothy A49 | Director | Buy | 57,598 | $9.27 | $534,094.73 | +14.3% | |
| Nov 13, 2017 | Cautreels Werner | President And CEO | Buy | 20,000 | $9.31 | $186,250.00 | +6.6% | |
| Nov 10, 2017 | Springer Timothy A49 | Director | Buy | 53,338 | $9.19 | $490,437.17 | +3.5% |